# Study of a Novel Antipsychotic ITI-007 in Schizophrenia

> **NCT01499563** · PHASE2 · COMPLETED · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 335 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ITI-007
- **DRUG:** Placebo
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01499563
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-08
- **Final completion:** 2013-11
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01499563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01499563, "Study of a Novel Antipsychotic ITI-007 in Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01499563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*